Roche Natural History study will soon start in UK and Germany. Over a period of 15 months, participants will be observed to measure the progression of Huntington’s Disease. Following the observation, all participants will be offered the Huntingtin Lowering drug RG6042.

Three clinics in Germany and 4 in the UK will soon start recruiting participants for the Roche Natural History study.

First, participants in the study will be observed for 15 months without receiving any treatment. Following the observation, all participants will be offered the Huntingtin Lowering drug RG6042.

Observation without treatment – why?

RG6042, previously known as IONIS-HTTRx, have shown good results. It has proven to lower the Huntingtin protein in the brain and improved symptoms over a short period of time.

Read more: Drug seems to improve symptoms

However, to know how the disease-causing Huntingtin protein works, it is important to measure it over a longer period of time. During this period, participants can’t receive any drug.

By mapping the baseline of the disease, researchers are able to better understand the disease itself, the symptoms and how the drug ‘actually’ works.

The sites that will be involved in the Roche Natural History study is:

Germany
Berlin – Charite University Berlin
Bochum – Ruhr-University of Bochum
Ulm – Ulm University Hospital
The Roche Germany Medical Information team can be contacted for more information about these sites/the study: (+49) 07624-14-2015

United Kingdom
Birmingham – University Hospitals Birmingham
Cardiff – University Hospital of Wales
London – University College London
Manchester – University of Manchester, St. Mary’s Hospital
The Roche UK Medical Information team can be contacted for more information about these sites/the study: (+44) 0800 3281629 or medinfo.uk@roche.com

Categories: NewsResearch